Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

PYRUKYND

Rare Disease news

Rare Diseases Today—May 28, 2026

This week’s Rare Diseases update highlights regulatory progress, late-stage…

Hematology

Hematology Today—May 25, 2026

This week’s Hematology update highlights regulatory approvals, reimbursement…

Hematology

Hematology Video Recap—March 9, 2026

This biweekly Hematology video recap highlights regulatory approvals, priority…

Hematology

Hematology Today—March 9, 2026

This week’s Hematology update highlights regulatory approvals, priority review…

Rare Disease news

Rare Diseases Weekly News - June 12th 2025

🔬 Rare Diseases Update: Orphan Drug Wins, Genomic Breakthroughs, Global…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
LucidWargames
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Obesity Today—June 23, 2026
LabGenius and LG Chem Advance Multispecific Antibody Partnership | Lucid Diligence Brief
Vedana Therapeutics Advances Migraine Antibody Pipeline | Lucid Diligence Brief
Hematology Today—June 22, 2026
Oncology Today—June 22, 2026

Tags

ABP-745 AMCHEPRY American Urological Association BRAIx Risk Score drug discovery partnerships EB613 ELEVATE-HFpEF ENHERTU Exosomes Eyenuk EyeArt FluoGuide Fractional Flow Reserve frexalimab G2GBIO GE HealthCare Getha IMAAVY Influenza Vaccine Intercept Pharmaceuticals K-cell technology label update Leucovorin Linerixibat LOJUXTA LUMEVOQ MB097 Metabolic Surgery mNexspike molecular glue degrader Moleculin NT-proBNP Nutrition guidelines Ocrelizumab pouchitis progressive MS Rapport Therapeutics Spinal muscular atrophy type 1 Stablepharma SVT-001 transformers AI Ultra-processed foods VALANX Biotech verapamil SR XOSPATA Xtandi

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Obesity Today—June 23, 2026
LabGenius and LG Chem Advance Multispecific Antibody Partnership | Lucid Diligence Brief
Vedana Therapeutics Advances Migraine Antibody Pipeline | Lucid Diligence Brief
Hematology Today—June 22, 2026
Oncology Today—June 22, 2026

TAGS

ABP-745 AMCHEPRY American Urological Association BRAIx Risk Score drug discovery partnerships EB613 ELEVATE-HFpEF ENHERTU Exosomes Eyenuk EyeArt FluoGuide Fractional Flow Reserve frexalimab G2GBIO GE HealthCare Getha IMAAVY Influenza Vaccine Intercept Pharmaceuticals K-cell technology label update Leucovorin Linerixibat LOJUXTA LUMEVOQ MB097 Metabolic Surgery mNexspike molecular glue degrader Moleculin NT-proBNP Nutrition guidelines Ocrelizumab pouchitis progressive MS Rapport Therapeutics Spinal muscular atrophy type 1 Stablepharma SVT-001 transformers AI Ultra-processed foods VALANX Biotech verapamil SR XOSPATA Xtandi

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy